Drug intelligence / Profile preview

Pearl-102

Development stage: Preclinical
Lead developer: PearlsInMires
Modality: Small Molecules
Administration: Oral

Overview

Pearl-102 is a small molecule combination therapy being developed by PearlsInMires for the treatment of gastrointestinal (GI) solid tumors. The drug candidate is designed to target Poly(ADP-ribose) glycohydrolase (PARG) and Schlafen 11 (SLFN11). PARG is a critical enzyme in the DNA damage response, responsible for degrading poly(ADP-ribose) (PAR) chains; its inhibition leads to PAR accumulation, replication stress, and cell death. SLFN11 is a DNA/RNA helicase that sensitizes cells to DNA-damaging agents by blocking replication forks. Pearl-102 is currently in the IND-enabling phase, with the company aiming to complete these studies by 2026.

Targets

SLFN11 (Schlafen family member 11)PARG (Poly(ADP-ribose) glycohydrolase)

Beyond the preview

Go deeper on Pearl-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pearl-102.

Explore the full profile